A type of acetylated galactopyranosan-rhamnose, its preparation method and application
Acetylated galactopyrostan sulfate was prepared by mild acid hydrolysis and hydrophilic chromatography-high resolution mass spectrometry, solving the problem of structural analysis of Chlorella polysaccharides and revealing its activity in inhibiting platelet aggregation and deformation, which has important potential for clinical application.
Patent Information
- Application Number
- CN202611584771.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-14
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies are insufficient to resolve the fine structure of Chlorella polysaccharides, especially the location and distribution of sulfation and acetylation modifications, which cannot explain the structure-activity relationship of their biological activity. Furthermore, existing antiplatelet aggregation drugs have side effects.
Acetylated galactopyrostan sulfate was prepared by mild acid hydrolysis combined with hydrophilic chromatography-high resolution mass spectrometry and separation and purification using a DEAE-Sepharose Fast Flow column. The monosaccharide composition, monosaccharide sequence, sulfate group, acetyl group and methyl group substitution positions of the oligosaccharide were determined, and its main structural domains were identified.
The accurate structure of acetylated galactosulfate-rhamnose was determined, and its activity in inhibiting platelet aggregation and deformability was discovered, providing new prospects for clinical applications, especially in drug development for the prevention and treatment of thrombosis, coronary heart disease, angina pectoris and acute myocardial infarction.
Smart Images

Figure CN123106941A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to an acetylated galactosulfate-rhamnosaccharide, its preparation method and application, specifically to an acetylated galactosulfate-rhamnosaccharide derived from Chlorella, its preparation method and application, belonging to the fields of biotechnology and chemical technology. Background Technology
[0002] Chlorella belongs to the phylum Chlorophyta, order Chlorococcales, family Chlorellaceae, and genus Chlorella. Rich in proteins, lipids, polysaccharides, chlorella growth factors, vitamins, natural pigments, and minerals, Chlorella has been certified by the Food and Agriculture Organization of the United Nations (FAO) as a green and healthy food and is widely used in aquaculture, cosmetics, medicine, and environmental protection, showing broad development prospects. Chlorella contains 10%-25% polysaccharides, which possess antioxidant, lipid-lowering, anti-asthmatic, anti-tumor, immunomodulatory, and neuroprotective activities. Chlorella polysaccharides have complex structures, mainly composed of various monosaccharides such as glucose, galactose, mannose, rhamnose, xylose, arabinose, glucosamine, and glucuronic acid. The sugar chains also have branches of uronic acid, galactose, rhamnose, or arabinose. Some sugar residues also have methylation, sulfate, and acetylation modifications, indicating that Chlorella has a wide variety of polysaccharides with complex structures.
[0003] Rhamnium sulfate is a unique sulfated polysaccharide mainly composed of rhamnose and sulfate groups, primarily derived from green algae and microalgae. Existing research indicates that rhamnium derived from green algae such as Ulva, Reef Algae, and Ulva prolifera has a structure mainly consisting of glucuronic acid-branched rhamnium sulfate and rhamnium-galacturonic acid polysaccharides, with no methylation or acetylation modifications found on the sugar chains.
[0004] Current research has found that microalgae contain relatively abundant rhamnose polysaccharides, but their structures are quite complex. The polysaccharide structures of Chlorella polysaccharides vary significantly among different varieties and sources. For example, in 2007, a study isolated a polysaccharide composed of galactose, rhamnose, and arabinose from a single-celled, high-lipid mutant strain of Chlorella kessleri. This polysaccharide had a specific main chain sequence and exhibited branch modifications of both galactose and xylose. In 2019, researchers isolated an extracellular polysaccharide composed of galactose and rhamnose from the culture medium of Chlorella vulgaris. Methylation and GC-MS analysis confirmed that this polysaccharide contained multiple glycosidic bond linkages and various methylated pentose and hexose structures. In 2020, another researcher isolated a rhamnan from the culture medium of Chlorella vulgaris. This rhamnan was mainly composed of a main chain structure formed by repeating rhamnose units, with some branches connected to galactose or arabinose oligosaccharides. Although existing technologies have been used to conduct extensive research on intracellular and extracellular polysaccharides of Chlorella, no highly sulfated and acetylated rhamnose structures have been found, and the exploration of related specific polysaccharide resources remains a gap.
[0005] Due to the complex structure of microalgal polysaccharides, the industry currently employs ion exchange chromatography, size exclusion gel chromatography, methylation analysis, and NMR to analyze their structures. These methods require complex separation, purification, and derivatization steps, including ion exchange chromatography purification, degradation, gel chromatography purification, desalting, and methylation, resulting in a very large workload and long processing time. Furthermore, the complex composition of microalgal polysaccharides leads to significant overlap of NMR absorption peaks, making analysis difficult.
[0006] In summary, although complex galactans and rhamnosaccharides have been discovered in *Chlorella*, only the glycosidic bond types and average structures of various monosaccharides can be preliminarily determined. The sequences connecting different monosaccharides and the main structural domains of the glycan chains cannot be determined, nor can the precise locations and distribution patterns of sulfation and acetylation be determined, thus failing to explain the structure-activity relationship of microalgal polysaccharides. Therefore, the industry urgently needs a simple and accurate method for analyzing the structures of microalgal polysaccharides. With the maturity of biomass spectrometry technology, analytical techniques combining mass spectrometry with glycomics to analyze the fine structures of complex polysaccharides have matured, providing technical support for the fine structural analysis of complex polysaccharides.
[0007] In the field of cardiovascular disease, platelet thrombosis caused by abnormal platelet activation is the initial step in arterial thrombosis. Previous studies have found that antiplatelet aggregation drugs can block platelets from participating in the thrombus formation process. Clinically, antiplatelet drug treatment has been shown to reduce the incidence of non-fatal myocardial infarction and stroke by about 35%. However, commonly used antiplatelet drugs such as aspirin have side effects such as easy bleeding, thrombocytopenia, and osteoporosis. Therefore, the discovery of safe and effective new natural antiplatelet active ingredients is of great clinical significance.
[0008] Current research has found that active ingredients such as heparin and fucoidan sulfate have good inhibitory activity on platelet aggregation. However, there are currently no research reports on the effects of rhamnosaccharide sulfate on platelet aggregation and deformability, which leaves a huge research gap and application value. Summary of the Invention
[0009] The technical problem to be solved by this invention is to address the shortcomings of existing technologies by providing an acetylated galactose sulfate-rhamnose polysaccharide, its preparation method, and its application. The acetylated galactose sulfate-rhamnose polysaccharide of this invention has sulfate and acetyl substitutions, and also has a hexose sulfate branch, without uronic acid. The high rhamnose and sulfate content endows it with excellent activity in inhibiting platelet aggregation and deformability, inhibiting the release of aggregation-promoting factors and thrombotic factors from dense granules and α-granules in platelets. The acetylation of the hydroxyl groups on rhamnose reduces the polarity of the polysaccharide, giving it better biocompatibility, increasing its binding activity to platelets, and inhibiting platelet aggregation and deformability.
[0010] To achieve the above objectives, the present invention adopts the following technical solution:
[0011] This invention first provides a method for preparing acetylated galactopyranoside-rhamnosaccharide, comprising the following steps:
[0012] (1) The dry Chlorella powder was made into a suspension with distilled water and the cell wall was broken in a high pressure homogenizer to obtain the cell wall broken algae liquid;
[0013] (2) Add a mixture of alkaline protease and neutral protease to the broken algae solution and enzymatically hydrolyze for 24 h. Then, inactivate the enzyme by boiling water bath, cool and centrifuge, collect the supernatant, and concentrate under vacuum to obtain the enzymatic hydrolysate.
[0014] (3) Add ethanol to the enzymatic hydrolysate for precipitation, then centrifuge and discard the supernatant. Collect the solid as Chlorella crude polysaccharide.
[0015] (4) The crude polysaccharide was dissolved in distilled water and separated and purified using a DEAE-Sepharose Fast Flow column. It was eluted with distilled water, 0.2 mol / L sodium chloride solution and 0.4 mol / L sodium chloride solution, respectively. The 0.4 mol / L sodium chloride solution eluent was collected and subjected to ultrafiltration membrane desalting, vacuum concentration and freeze drying to obtain the acetylated galactopyranoside sulfate.
[0016] In the above technical solution, in step (1), the solid-liquid ratio (g:mL) of the Chlorella dry algae powder and distilled water is 0.5-1.5:2-4, preferably 1:3.
[0017] In the above technical solution, in step (2), the alkaline protease is a serine protease; the neutral protease is a trypsin; the mass ratio of the alkaline protease and the neutral protease is 2-3:1-2, preferably 2.5:1.5.
[0018] In the above technical solution, in step (2), the enzymatic hydrolysis conditions are: enzymatic hydrolysis at pH 7.0±0.1 and 50±5℃ for 24±1h, followed by inactivation of the enzyme by boiling in a water bath for 5±1min; and centrifugation at 20±1℃ followed by collection of the supernatant.
[0019] In the above technical solution, in step (3), 90% (w:v) ethanol is added to the enzymatic hydrolysate, and the volume ratio of the enzymatic hydrolysate to ethanol is 0.5-1.5:7-9, preferably 1:8; the precipitate is allowed to stand and then centrifuged to discard the supernatant. The precipitate is washed several times with 95% (w:v) ethanol to obtain Chlorella crude polysaccharide.
[0020] The second objective of this invention is to provide an acetylated galactosulfate-rhamnosaccharide prepared by the above-mentioned method, wherein the acetylated galactosulfate-rhamnosaccharide has a weight-average molecular weight of 20.42 kDa, a dispersion index of 2.43, a sulfate molar content of 12.75%, and a protein content of 2.45%.
[0021] In the above technical solution, the acetylated galactosulfate-rhamnose has the following monosaccharide molar composition: rhamnose 36.6%, galactose 30.4%, glucose 9.4%, mannose 5.4%, glucosamine 5.6%, arabinose 5.0%, xylose 3.7%, glucosamine 1.5%, and glucuronic acid 2.4%.
[0022] In the above technical solution, the acetylated galactosulfate-rhamnose comprises four domains and one branch: an acetylated hexose sulfate (galactose, glucose, or mannose) domain, a rhamnose sulfate domain, an acetylated rhamnose sulfate domain, an acetylated and methylated hexose sulfate-rhamnose domain, and a hexose sulfate disaccharide branch. Domain analysis of acetylated galactosulfate-rhamnose primarily employs mild acid degradation combined with hydrophilic chromatography-high-resolution multistage mass spectrometry to analyze the monosaccharide composition, monosaccharide linkage sequences, substitution positions of sulfate, acetyl, and methyl groups, and types of glycosidic bonds in all oligosaccharides within the degradation products of acetylated galactosulfate-rhamnose. The study revealed that the complex acetylated galactosulfate-rhamnose mainly contains four domains, and the substitution positions of sulfate, acetyl, and methyl groups on the sugar chains and the distribution patterns of the sugar chains were accurately determined, providing a structural basis for the structure-activity relationship study of the bioactivity of acetylated galactosulfate-rhamnose.
[0023] In the above technical solution, the acetylated hexose sulfate domain has a main chain composed of 2-4 →3)-α-D-hexose residues, wherein the hexose residues are selected from galactose, glucose, or mannose, and have 1-2 sulfate groups and 1-3 acetyl groups modified. The oligosaccharide units of this domain are mainly composed of 2-sulfohexose Hex(2S), 2-acetylated hexose Hex(2Ac), and 2-acetyl-4-sulfate disubstituted hexoses, forming Hex(2Ac,4S). This indicates that galactose, mannose, and glucose also have high levels of sulfation and acetylation modifications, as well as trace amounts of methylation modifications. The main oligosaccharide structural fragments of this domain are Hex(2S)-1,3-Hex(2S)-Hex(4Ac), Hex(2S)-1,3-Hex-Hex(2Ac,4S), and Hex(2S)-1,3-Hex(2S)-1,3-Hex(2Ac)-Hex(2Ac). 、Hex3S2-Ac1-Me.
[0024] In the above technical solution, the rhamnose sulfate domain has a main chain composed of 2-4 oligosaccharides consisting of repeating units of (3)-α-D-rhamnose-(1)-α-D ...
[0025] In the above technical solution, the acetylated rhamnose sulfate domain has a main chain composed of 3-8 oligosaccharides consisting of 3-8 repeating units of α-D-rhamnose (α-D-Rhamnose). Each oligosaccharide has 2-3 sulfate groups and 1-5 acetyl groups modified on it. It is mainly composed of rhamnose Rha, 2-sulfated rhamnose Rha (2S), and 2-acetylrhamnose Rha (2Ac). It is the first time that sulfate and acetyl groups have been found to be alternately linked on the rhamnose chain. At the same time, a small amount of rhamnose with acetyl and sulfate disubstituted rhamnose groups are present. Rha(2Ac,4S) is a limonose domain whose main oligosaccharide segments are Rha(2S)-1,3-Rha(2Ac)-1,3-Rha(2S)-1,3-Rha(2Ac)-1,3-Rha(2S)-1,3-Rha(2Ac) and Rha(2S)-1,3-Rha(2Ac)-1,3-Rha(2S)-1,3-Rha(2Ac)-1,3-Rha-1,3-Rha(2Ac)-1,3-Rha(2Ac,4S).
[0026] In the above technical solution, the acetylated and methylated hexose sulfate-rhamnose domain is mainly composed of repeating disaccharide units Hex1→3Rha linked alternately with galactose (or mannose, glucose) and rhamnose via 1→3 bonds. The oligosaccharides have sulfate, acetyl, and methyl groups substituted on them. The sugar chains constituting this domain are mainly composed of rhamnose sulfate Rha, 2-rhamnose sulfate Rha(2S), 4-rhamnose sulfate Rha(4S), 2-acetyllose rhamnose Rha(2Ac), hexose Hex, 2-hexose sulfate Hex(2S), 4-hexose sulfate Hex(4S), 2-acetyllose hex(2Ac), and a small amount of methylated oligosaccharides such as Rha(2Me), Rha(2Me,4Me), and Hex(2Me,4Me), with acetyl and sulfate groups alternately linked on the sugar chains. The main oligosaccharide structural segments of this domain are:
[0027] Rha(2S)-1,3-Hex(2Ac)-1,3-Rha(2S)-1,3-Hex(2Ac)-1,3-Rha-1,3-Hex(4S);
[0028] Rha(2S)-1,3-Hex(2S)-1,3-Rha(2Ac)-1,3-Hex(2Ac)-1,3-Rha-1,3-Hex(4S);
[0029] Rha(4S)-1,3Hex-1,3-Rha(4S)-1,3-Hex-1,3-Rha(2Me,4Me)-1,3-Hex.
[0030] In the above technical solution, the sulfated hexose disaccharide branch is a disaccharide composed of glucose, galactose, glucose, or mannose linked by 1,3 glycosidic bonds, with sulfate groups at the C2 and C4 positions of the hexose. The main structural segments are Hex(2S)-1,3-Hex(4S) and Hex(2S)-1,3-Hex(2S), while also containing a small amount of Hex(2S,4S)-1,3-Hex, which serve as branches attached to the galacto-rhamnose sugar chain.
[0031] A third objective of this invention is to provide the application of the acetylated galactosulfate-rhamnosaccharin described above in the preparation of drugs that inhibit platelet aggregation and deformability.
[0032] The fourth objective of this invention is to provide the application of the acetylated galactosulfate-rhamnosaccharin described above in the preparation of a drug that inhibits platelet aggregation factors.
[0033] The fifth objective of this invention is to provide the application of the acetylated galactopyranosan sulfated as described above in the preparation of drugs for the prevention and treatment of platelet-related diseases; the platelet-related diseases refer to any one or more of thrombosis, coronary heart disease, angina pectoris, and acute myocardial infarction.
[0034] Compared with existing technologies, it has the following beneficial effects:
[0035] (1) Using mild acid hydrolysis combined with hydrophilic chromatography-high resolution mass spectrometry and multi-stage mass spectrometry, the structure of all oligosaccharides in the degradation products of complex acetylated galactosulfate-rhamnose was analyzed. The monosaccharide composition, monosaccharide sequence, sulfate group, acetyl group and methyl group substitution positions of oligosaccharides were resolved. Thus, the main structural domains of acetylated galactosulfate-rhamnose were discovered, and the distribution pattern of acetyl group, methyl group and sulfate group in novel acetylated galactosulfate polysaccharides was discovered. The structure of complex Chlorella polysaccharides was better resolved, providing a structural basis for fine structure analysis and structure-activity relationship research of Chlorella polysaccharides.
[0036] (2) The acetylated galactosulfate-rhamnose of the present invention has sulfate and acetyl substitutions, and also has a hexose sulfate branch, without uronic acid. Its sulfate and rhamnose content is significantly higher than that of rhamnose sulfate derived from green algae such as *Ulva prolifera* and *Ulva urticata*. The high rhamnose and sulfate content endows it with excellent activity in inhibiting platelet aggregation and deformability, and inhibits the release of aggregation-promoting factors and thrombotic factors from dense granules and α-granules in platelets. The acetylation of the hydroxyl groups on rhamnose reduces the polarity of the polysaccharide, endows the polysaccharide with better biocompatibility, improves its binding activity with platelets, and inhibits platelet aggregation and deformability. The novel acetylated galactosulfate-rhamnose of the present invention has important clinical significance and application prospects in the prevention and treatment of platelet-related thrombosis, coronary heart disease, angina pectoris, and acute myocardial infarction. Attached Figure Description
[0037] Figure 1 To verify the size exclusion gel chromatography spectrum of acetylated galactopyranoside sulfate in Example 1;
[0038] Figure 2 To verify the chromatogram of monosaccharide composition of acetylated galactopyranosan by PMP pre-column derivatization-HPLC method in Example 2;
[0039] Figure 3 To verify the Fourier transform infrared spectrum of acetylated galactopyranoside sulfate in Example 3;
[0040] Figure 4 To verify the total ion chromatogram of acetylated galactopyranoside sulfate degradation products analyzed by HILIC-FTMS in Example 4;
[0041] Figure 5 To verify the HCD MS / MS spectrum of Hex2S2 ions with m / z 250.0074 (z=1) in Example 5;
[0042] Figure 6 To verify the molecular structure diagram of Hex2S2 in Example 5;
[0043] Figure 7 To verify the HCD MS / MS spectrum of the trisaccharide Hex3S2+Ac1 ion m / z 352.0388 (z=2) in Example 5;
[0044] Figure 8 To verify the molecular structure diagram of the trisaccharide Hex3S2+Ac1 in Example 5;
[0045] Figure 9 To verify the HCD MS / MS spectrum of the parent ion of the tetrasaccharide Hex4S2+Ac2 in Example 5, m / z 454.0712 (z=2);
[0046] Figure 10 To verify the molecular structure diagram of the tetrasaccharide Hex4S2+Ac2 in Example 5;
[0047] Figure 11 To verify the HCD MS / MS spectrum of the parent ion of disaccharide Rha2S2 in Example 5, m / z 234.0123 (z=2);
[0048] Figure 12 To verify the schematic diagram of the molecular structure of the disaccharide Rha2S2 in Example 5;
[0049] Figure 13To verify the HCD MS / MS spectrum of the parent ion (m / z = 307.0418, z = 2) of the trisaccharide Rha3S2 in Example 5;
[0050] Figure 14 To verify the molecular structure diagram of the trisaccharide Rha3S2 in Example 5;
[0051] Figure 15 To verify the HCD MS / MS spectrum of the parent ion (m / z = 422.0815, z = 2) of the tetrasaccharide Rha4S2+Ac2 in Example 5;
[0052] Figure 16 To verify the schematic diagram of the molecular structure of the tetrasaccharide Rha4S2+Ac2 in Example 5;
[0053] Figure 17 To verify the HCD MS / MS spectrum of the hexasaccharide Rha6S3+Ac3 (m / z= 419.0798, z=3) in Example 5;
[0054] Figure 18 To verify the molecular structure diagram of the hexasaccharide Rha6S3+Ac3 in Example 5;
[0055] Figure 19 To verify the HCD MS / MS spectrum of the trisaccharide Hex1Rha2S2 (m / z = 315.0396, z = 2) in Example 5;
[0056] Figure 20 To verify the molecular structure diagram of the trisaccharide Hex1Rha2S2 in Example 5;
[0057] Figure 21 To verify the HCD MS / MS spectrum of the tetrasaccharide Hex2Rha2S2 (m / z = 396.0655, z = 2) in Example 5;
[0058] Figure 22 To verify the schematic diagram of the molecular structure of the tetrasaccharide Hex2Rha2S2 in Example 5;
[0059] Figure 23 To verify the HILIC-ESI-MS / MS spectrum of the hexasaccharide Hex3Rha3S3+Ac2 (m / z=421.0766, z=3) in Example 5;
[0060] Figure 24 To verify the molecular structure diagram of the hexasaccharide Hex3Rha3S3+Ac2 in Example 5;
[0061] Figure 25To verify the HILIC-ESI-MS / MS spectrum of the hexasaccharide Hex3Rha3S2+Me2 (m / z= 564.1360, z=2) in Example 5;
[0062] Figure 26 To verify the molecular structure diagram of the hexasaccharide Hex3Rha3S2+Me2 in Example 5;
[0063] Figure 27 The effect of acetylated galactosulfate-rhamnian polysaccharide on the ability of thrombin to induce the release of ADP and 5-HT from dense human platelets in Example 6 is shown in the graph, where: Figure 27 Image a shows the induced release of ADP from dense platelet granules in rats. Figure 27 Figure b shows the induced release of 5-HT from dense platelets in rats; different lowercase letters above the bars in the bar chart represent significant differences between groups (P < 0.05).
[0064] Figure 28 The effect of acetylated galactosulfate-rhamnian on the ability of thrombin-induced release of PF4 and β-TG from rat platelet α-granules is shown in the figure in Example 6. Figure 28 Figure a shows the induced release of β-TG from α-granules in rat platelets; Figure 28 Figure b shows the PF-4 release induced by platelet α-granules in rats; different lowercase letters above the bars in the bar chart represent significant differences between groups (P < 0.05).
[0065] Figure 29 The effect of acetylated galactosulfate-rhamnian on the ability of thrombin-induced release of TXB2 and PGF1α from rat platelets in Example 6 is shown in the figure, where: Figure 29 Figure a shows the induction of PGF1α release from rat platelets; Figure 29 Figure b shows the induced release of TXB2 from rat platelets; different lowercase letters above the bars in the bar chart represent significant differences between groups (P < 0.05).
[0066] Figure 30 The effect of acetylated galactosulfate-rhamnian on thrombin-induced platelet deformability in rats, as shown in Example 6, is illustrated in the figure below: Figure 30 Group A is the blank group; Figure 30 Group B represents the thrombin induction group; Figure 30 Group C is 10 μM PGE1; Figure 30 The middle D group was the 10 μM PGE1+ thrombin group; Figure 30 Group I was 70 μg / mL rhamnose polysaccharide; Figure 30 The middle group (J) consisted of 70 μg / mL rhamnose polysaccharide and thrombin. Detailed Implementation
[0067] The following describes in detail the specific embodiments of the technical solution of the present invention, but the present invention is not limited to the following description:
[0068] Example 1:
[0069] An acetylated galactopyranosan-rhamnosaccharide was prepared by the following method:
[0070] (1) Take 100 g of Chlorella powder, add 300 mL of distilled water to make a uniform suspension, and use a high-pressure homogenizer to break the cell wall.
[0071] (2) Add 2.5 g alkaline protease and 1.5 g neutral protease to the suspension and stir and hydrolyze for 24 h in a 50 ℃ water bath; then inactivate the enzyme by boiling in a water bath for 5 min and cool to room temperature; centrifuge (4000 × g, 15 min, 20 ℃) and take the supernatant; concentrate the obtained supernatant under vacuum to 100 mL to obtain the hydrolysate;
[0072] (3) Add 800 mL of 90% ethanol to 100 mL of enzyme hydrolysate, place at 4℃ for 12 h, then centrifuge (4000 × g, 15 min, 20 ℃) and discard the supernatant. Wash the precipitate three times with 95% ethanol to obtain the crude polysaccharide of Chlorella vulgaris.
[0073] (4) Purification of polysaccharides:
[0074] Take 1g of crude polysaccharide, dissolve it in 100mL of distilled water, add it to a DEAE-Sepharose Fast Flow anion exchange column (300mL), and elute with distilled water, 0.2 mol / L sodium chloride solution, and 0.4 mol / L sodium chloride solution respectively. Collect the 0.4 mol / L sodium chloride solution eluent. Use an ultrafiltration membrane with a molecular weight cutoff of 5 kDa to desalt the eluent, collect the fraction with a molecular weight greater than 5 kDa, concentrate under vacuum, and freeze-dry to obtain acetylated galactopyranoside sulfate dry product.
[0075] After cell wall disruption, enzymatic hydrolysis, water extraction, and ion chromatography purification, the acetylated galactosulfate-rhamnose obtained from Chlorella powder was a light yellow powder. In three parallel experiments, the yield was 4.2% ± 0.14%, the sulfate content was 12.75% ± 1.21%, and the protein content was 2.45% ± 0.13%.
[0076] Verification Example 1: Determination of Polysaccharide Molecular Weight
[0077] 1. Experimental Method: The acetylated galactopyranin-sulfate sample obtained in Example 1 was dissolved in 0.1 mol / L Na2SO4 solution, and the molecular weight of the polysaccharide was determined by high performance gel size exclusion chromatography (HPSEC). Chromatographic parameters: Agilent 1260 high performance liquid chromatography system; Ohpak SB-804 HQ gel chromatography column (8.0 × 300 mm, 10 μm); injection volume 20 μL; mobile phase 0.1 mol / L Na2SO4; column temperature 30 ℃; mobile phase flow rate 0.4 mL / min; time 35 min; differential refractive index detector (RID) selected; dextran standards with molecular weights of 4, 5, 20, 40, and 50 kDa were dissolved in 0.1 mol / L Na2SO4 solution and subjected to the same HPSEC detection. A standard curve was plotted using the logarithm of molecular weight (lgM) and retention time (t), and the regression equation was y = -0.1966x + 9.3922 (R 2 =0.9963).
[0078] 2. Experimental Results: The size exclusion gel chromatogram of acetylated galactopyranoside-rhamnite is shown below. Figure 1 As shown in Table 1, the molecular weight calculation results are as follows:
[0079] Table 1. Results of molecular weight calculation
[0080] Retention time / min Weight-average molecular weight / kDa Dispersion coefficient percentage% 11.5-13.2 660.69 2.23 6.60 13.5-20.2 20.41 2.43 93.40
[0081] Depend on Figure 1 As shown in Table 1, the polysaccharides have two elution peaks. 93.4% of the polysaccharides are with a weight-average molecular weight of 20.41 kDa (dispersion index 2.43), which is lower than that of rhamnosaccharides from green algae. A small amount of high molecular weight polysaccharides with a weight-average molecular weight of 660.691 kDa (dispersion index 2.23) is also present.
[0082] Verification Example 2: Determination of Polysaccharide and Monosaccharide Composition
[0083] 1. Experimental Method: The monosaccharide composition of rhamnite was determined by pre-column derivatization with 1-phenyl-3-methyl-5-pyrazolone (PMP-HPLC). 10 μL of each standard (totaling 100 μL) was added to a 2 mL centrifuge tube and mixed thoroughly. Then, 130 μL of 0.3 mol / L NaOH solution and 150 μL of PMP derivatizing agent were added. After vortexing, the mixture was reacted in a 70°C water bath in the dark for 30-40 min. After cooling in the dark, 130 μL of 0.3 mol / L HCl solution was added, followed by 500 μL of chloroform. The mixture was thoroughly shaken and extracted (in a fume hood). The lower layer was removed, and the extraction was repeated 20 times to remove any underived PMP reagent. After centrifugation at 6000 × g for 5 min, 200 μL of the upper aqueous phase was collected, diluted 3 times with ultrapure water, and filtered through a 0.22 μm ultrafiltration membrane to obtain the standard derivative.
[0084] Rhamnan was prepared into a 10 mg / mL solution. 200 μL of this solution was added to an ampoule, followed by 1 mL of 2 mol / L trifluoroacetic acid solution. The ampoule was purged with nitrogen and sealed. The solution was then digested in a 110°C oven for 4 h to obtain the digest. The digest was dried in a 60°C water bath to remove the trifluoroacetic acid, then reconstituted with 200 μL of ultrapure water. This process was repeated three times to remove all trifluoroacetic acid. The solution was then adjusted to neutral with 0.3 mol / L NaOH solution and brought to a final volume of 200 μL. 90 μL of the sample was mixed with 10 μL of lactose internal standard and subjected to PMP derivatization to obtain a monosaccharide derivative of rhamnan. 1 μL of the monosaccharide derivative solution was analyzed by high-performance liquid chromatography (HPLC).
[0085] Chromatographic parameters: Agilent 1260 high performance liquid chromatograph; Poroshell EC-C18 separation column (4.6 × 150 mm, 2.7 μm); 240 nm ultraviolet detector (VWD); flow rate 0.4 mL / min; column temperature 30 ℃; injection volume 10 μL. Mobile phase A: 0.05 mol / L phosphate buffer: acetonitrile = 82 : 18 (v / v); Mobile phase B: 0.05 mol / L phosphate buffer: acetonitrile = 65 : 35 (v / v); Mobile phase gradient elution: 0.00-49.00 min, B 3.0%-20.0%; 49.00-50.00 min, B 20.0%-100.0%; 50.00-52.00 min, B maintained at 100.0%; 52.00-53.00 min, B 100.0%-3.0%; 53.00-54.00 min, B maintained at 3.0%.
[0086] 2. Experimental Results: The chromatogram of monosaccharide composition of acetylated galactopyranosulfate-rhamnose analyzed by PMP pre-column derivatization-HPLC method is shown below. Figure 2As shown in Table 2, the monosaccharide composition of acetylated galactosulfate-rhamnite is as follows:
[0087] Table 2. Monosaccharide composition of acetylated galactosulfate-rhamnose
[0088] Types of monosaccharides Rhamnose Galactose glucose Mannose Arabic sugar Xylose galactosamine Glucosamine Glucuronic acid Mole percentage % 36.6±1.6 30.4±2.3 9.4±1.0 5.4±0.9 5.0±1.2 3.7±1.2 1.5±0.2 5.6±0.3 2.4±1.5
[0089] Note: The total molar number of all monosaccharides is 100%, and the percentage content of each monosaccharide is a percentage of moles.
[0090] Depend on Figure 2 As shown in Table 2, rhamnose and galactose have the highest content, with molar percentages of 36.6% and 30.4%, respectively. It also contains certain amounts of glucose (9.4%), mannose (5.4%), and arabinose (5.0%), as well as trace amounts of xylose (3.7%), glucosamine (5.6%), galactosamine (1.5%), and glucuronic acid (2.4%).
[0091] Verification Example 3: Infrared Spectroscopic Analysis of Polysaccharides
[0092] 1. Experimental Method: Spectroscopic-grade potassium bromide was dried in a 110℃ oven for 10 h. The dried potassium bromide was then mixed with the sample to be tested and ground into powder (100:1), pressed into tablets, and detected using a NICOLET iS10 Fourier transform infrared spectrometer. The background scan count was 64 times, and the resolution was 2.0 cm⁻¹. -1 The detection wavelength range is 4000 cm. -1 -400 cm -1 The spectrum processing software used was OMNIC 9.0.
[0093] 2. Experimental Results: The Fourier transform infrared spectrum of acetylated galactopyranosan-rhamnose is shown below. Figure 3 As shown, by Figure 3 It can be seen that acetylated galactopyranoside sulfate at 3362 cm⁻¹ -1 1044 cm -1 The presence of strong OH stretching vibration peaks and COC stretching vibration peaks indicates that the extracted and separated rhamnose polysaccharide has a relatively high purity. At 2942 cm⁻¹ -1 The nearby weak peak is the CH stretching vibration peak of -CH3, which may originate from rhamnose itself or possibly from methylation. (At 1651.15 cm⁻¹) -1 The presence of a high C=O stretching vibration absorption peak nearby indicates the presence of a high C=O group, suggesting possible acetylation modification. At 1243 cm⁻¹ -1 The peak represents the stretching vibration of S=O, combined with the 839 cm peak. -1The nearby COS vibration peaks indicate that the polysaccharide contains a certain amount of sulfate. Therefore, it can be inferred that acetylated galactosulfate-rhamnosaccharide is a sulfated polysaccharide modified with acetylation and sulfate.
[0094] Verification Example 4: Structural Analysis of Oligosaccharides in Degradation Products using HILIC-FTMS and HILIC-CID-MSMS
[0095] 1. Test method:
[0096] (1) Degradation of polysaccharides
[0097] Dissolve 0.1 g of polysaccharide in 0.1 mol / L hydrochloric acid to prepare a concentration of 10 mg / mL. React at 100 °C for 1 h, then neutralize to pH 7.0 with 0.1 mol / L sodium hydroxide. Ultrafilter using a 1000 Da molecular weight cutoff membrane, collect the dialysate, and freeze-dry to obtain the degradation product of acetylated galactopyranoside sulfate.
[0098] (2) HILIC-FTMS and HILIC-CID-MSMS analysis of the structure of oligosaccharides in the degradation products
[0099] The degradation products of the prepared acetylated galactopyranoside sulfate were dissolved in ultrapure water to a concentration of 10 mg / mL. 100 μL of the sample solution was thoroughly mixed with acetonitrile (1:1), filtered through a 0.22 μm microporous membrane, and 20 μL of the filtrate was analyzed by HILIC-FTMS and HILIC-CID-MSMS.
[0100] High-performance liquid chromatography (HPLC) analysis conditions: Thermo UltiMate 3000 ultra-high performance liquid chromatograph; Luna 3μ HILIC hydrophilic column (2.0×150 mm, 2.7 μm); injection volume 10 μL; column temperature 25℃; mobile phase A: 5 mmol / L ammonium acetate solution (dissolved in ultrapure water) and mobile phase B: 98% (v / v) acetonitrile (dissolved in mobile phase A); gradient elution of mobile phase: 0–3 min, A 5.0%; 3–30 min, A from 5.0% to 35.0%; 30–35 min, A maintained at 35.0%; 35–40 min, A from 35.0% to 80.0%; 40–50 min, A maintained at 80.0%; 50–51 min, A from 80.0% to 5.0%; 51–60 min, A maintained at 5.0%; flow rate 150 μL / min.
[0101] ESI-FTMS analysis conditions: Thermo Q Exactive Orbitrap mass spectrometer; primary mass spectrometry resolution 70,000; primary mass spectrometry scanning mode: "Full MS-SIM" negative ion mode. Spray voltage 2.50 kV, sheath gas flow rate 40, auxiliary gas flow rate 10; capillary voltage and temperature -40 V and 320 °C; molecular weight scanning range 120–1500 Da;
[0102] CID-MSMS analysis conditions:
[0103] “Full MS - SIM” tandem “PRM” mode, MS / MS resolution 17500, stepped NCE energy: 20, 30, 35.
[0104] 2. Experimental Results:
[0105] 2.1. The total ion chromatogram of acetylated galactose sulfate-rhamnose degradation products analyzed by liquid chromatography-mass spectrometry is shown in the figure. Figure 4 As shown: The results of liquid chromatography-mass spectrometry analysis indicate that a total of 33 oligosaccharides with different structures were found in the degradation products, of which 49.54% were sulfated hexose oligosaccharides mainly composed of galactose (or glucose or mannose), and 47.5% were sulfated rhamnose oligosaccharides mainly composed of rhamnose.
[0106] 2.2 Analysis of the acetylated hexose sulfate domain
[0107] The analytical results of the acetylated hexose sulfate domain are shown in Table 3:
[0108] Table 3. HILIC-FT-MS analysis of the mass-to-charge ratio, charge number, and total ionic strength of hexose oligosaccharides in rhamnan degradation products.
[0109]
[0110] Hex: Hexose, which is either galactose or glucose; Pent: Pentose, which is either arabinose or xylose. Ac: Acetyl group; Me: Methyl group; S: Sulfate group; the numbers indicate the number of monosaccharides and groups.
[0111] Table 3 shows that acetylated hexose sulfates with a degree of polymerization of 2-4 account for 37.89% of the total oligosaccharides in the degradation products, with 1-3 acetyl groups modified. The main oligosaccharides are Hex2S2+Ac1, Hex3S2+Ac2, and Hex3S2+Ac1. 3。The degradation products also revealed that 6.9% of the oligosaccharides were hexose-disaccharides Hex2S1 and Hex2S1, suggesting that these hexose sulfates may act as side chains linked to galactose-rhamnose and were degraded from the main chain during degradation. A small amount of the trisaccharide Hex3S2+Ac1+Me3, which is simultaneously modified with methylation and acetylation, was also found, indicating that the hexose sulfate domain also has high levels of sulfation and acetylation modification, along with a small amount of methylation modification. Oligosaccharides with this structure have never been reported in other microalgae. Additionally, hexose-pentose sulfate heterooligosaccharides such as Hex1Pent1S1, Hex1Pent1S1+Ac1, and Hex2Rha2Pent1S2+Ac2, accounting for 4.74% of the total oligosaccharides, were also found.
[0112] 2.3 Analysis of the acetylated rhamnose sulfate domain
[0113] The analytical results of the acetylated rhamnose sulfate domain are shown in Table 4:
[0114] Table 4. HILIC-FT-MS analysis of the mass-to-charge ratio, charge number, and total ionic strength of rhamnosaccharide sulfate in rhamnosaccharide degradation products.
[0115]
[0116] Note: Rha: rhamnose; Hex: hexose, which is galactose or glucose; Pent: arabinose or xylose; S: sulfate; Ac: acetyl; Me: methyl; the numbers represent the number of monosaccharides and groups.
[0117] Table 4 shows that 20.35% of the total oligosaccharides obtained from degradation were rhamnose sulfate oligosaccharides with a degree of polymerization of 2-4, mainly Rha2S1, Rha2S2, and Rha3S2. Acetylated rhamnose sulfate oligosaccharides with a degree of polymerization of 3-8 were also discovered for the first time, accounting for 15.69% of the total oligosaccharides. Among them, Rha3S2+Ac1, Rha4S2+Ac2, Rha5S3+Ac2, and Rha6S3+Ac3 were the main oligosaccharides. The largest octasaccharide, Rha8S3+Ac5, has five acetyl groups, indicating that the rhamnose sulfate domain of *Chlorella vulgaris* has a high degree of acetylation, while oligosaccharides with this structure have not been found in other microalgae.
[0118] 2.4 Analysis of the acetylated hexose sulfate-rhamnose domain
[0119] For the first time, acetylated and methylated hexose sulfate-rhamnooligosaccharides with a degree of polymerization of 2-6 were also found in the degradation products, accounting for 11.46% of the total oligosaccharides. The main oligosaccharides were hexose sulfate-rhamnooligosaccharides (Hex1Rha2S2, Hex2Rha2S2), acetylated hexose sulfate-rhamnooligosaccharides (Hex2Rha2S2+Ac2, Hex3Rha3S3+Ac2), and methylated and acetylated hexose sulfate-rhamnooligosaccharides (Hex2Rha1S2+Ac2+Me1, Hex2Rha1S2+Ac2+Me1, Hex3Rha2S3+Ac2+Me3). This indicates that the hexose (galactose, glucose, or mannose) is directly linked to rhamnoose in the structural domain, and the hexose and rhamnoose are modified with sulfate, methyl, and acetyl groups. This complex structure is unique to Chlorella and has never been reported in other microalgae.
[0120] Verification Example 5: HILIC-HCD MS / MS analysis of the structure of sulfated oligosaccharides
[0121] To further determine the structural characteristics of various domains in acetylgalactosulfate rhamnosaccharides derived from Chlorella, we analyzed the structure of the sulfated oligosaccharides using HILIC-HCD MS / MS and resolved the structure using secondary mass spectrometry.
[0122] 5.1 HILIC-HCD MS / MS structural analysis of hexose sulfate and acetylated hexose sulfate oligosaccharides
[0123] (1) Structural analysis of Hex2S2:
[0124] The HCD MS / MS spectrum of hexose disaccharide Hex2S2 (m / z = 250.0074, z = 2) is shown below. Figure 5 As shown, the molecular structure diagram is as follows: Figure 6 As shown, it is speculated that the three isomers of this disaccharide are: Hex(2S)-1,3-Hex(4S), Hex(2S)-1,3-Hex(2S) and Hex(2S,4S)-1,3-Hex.
[0125] (2) HILIC-HCD MS / MS structural analysis of acetylated hexose sulfate:
[0126] (a) Structural analysis of Hex3S2+ Ac1:
[0127] The HCD MS / MS spectrum of the trisaccharide Hex3S2+Ac1 (m / z = 352.0388, z = 2) is shown below. Figure 7 As shown, the molecular structure diagram is as follows: Figure 8As shown, the two isomers of the trisaccharide are identified as Hex(2S)-1,3-Hex(2S)-Hex(4Ac) and Hex(2S)-1,3-Hex-Hex(2S,4Ac).
[0128] (b) Structural analysis of Hex4S2+Ac2:
[0129] The HCD MS / MS spectrum of the parent ion of Hex4S2+Ac2 (m / z=454.0712, z=2) is as follows: Figure 9 As shown, the molecular structure diagram is as follows: Figure 10 As shown, the three isomers of the tetrasaccharide are:
[0130] Hex(2S)-1,3-Hex-1,3-Hex(2Ac)-Hex(2Ac,4S);
[0131] Hex(2S)-1,3-Hex(2Ac)-1,3-Hex(2Ac,4S)-Hex;
[0132] Hex(2S)-1,3-Hex(2Ac,4S)-1,3-Hex(2Ac)-Hex;
[0133] Hex(2S)-1,3-Hex(2S)-1,3-Hex(2Ac)-Hex(2Ac).
[0134] In the sulfate-hexose domain, the sulfate group is located at the C2 or C4 position of the hexose, and the acetyl group is located at the C2 position of the hexose. Simultaneously, there are sulfate and acetyl disubstituted hexoses Hex(2Ac,4S).
[0135] 5.2 Structural analysis of rhamnosaccharide sulfate by HILIC-HCD MSMS:
[0136] (1) Structural analysis of Rha2S2:
[0137] The HCD MS / MS spectrum of the parent ion of rhamnobiose Rha2S2, m / z 234.0123 (z=2), is shown below. Figure 11 As shown, the molecular structure diagram is as follows: Figure 12 As shown, the main structure of Rha2S2 is Rha(4S)-1,3-Rha(2S), with a small amount of Rha-1,3-Rha(2S,4S).
[0138] (2) Structural analysis of Rha3S2:
[0139] The HCD MS / MS spectrum of the parent ion of the trisaccharide Rha3S2 (m / z = 307.0418, z = 2) is shown below. Figure 13 As shown, the molecular structure diagram is as follows: Figure 14 As shown, it is speculated that Rha(2S)-1,3-Rha-1,3-Rha(2S) is the main structure of this trisaccharide, with small amounts of Rha(2S)-1,3-Rha(2S)-1,3-Rha and Rha(2S,4S)-1,3-Rha-1,3-Rha.
[0140] 5.3 Structural analysis of acetylated rhamnosaccharide sulfate:
[0141] (1) Structural analysis of acetylated rhamnite sulfate Rha4S2+Ac2:
[0142] The HCD MS / MS spectrum of the parent ion (m / z = 422.0815, z = 2) of the tetrasaccharide Rha4S2+Ac2 is shown below. Figure 15 As shown, the molecular structure diagram is as follows: Figure 16 As shown, the tetrasaccharide has three isomers:
[0143] Rha(2S)-1,3-Rha(2Ac)-1,3-Rha(2S)-1,3-Rha(2Ac),
[0144] Rha(2S)-1,3-Rha(2Ac)-1,3-Rha(2S)-1,3-Rha(2Ac),
[0145] Rha(2S)-1,3-Rha(2Ac)-1,3-Rha(2Ac,4S)-1,3-Rha.
[0146] (2) Structural analysis of Rha6S3+Ac3:
[0147] The HCD MS / MS spectrum of acetylated hexasaccharide Rha6S3+Ac3 is as follows: Figure 17 As shown, the molecular structure diagram is as follows: Figure 18 As shown, the hexasaccharide has four isomers:
[0148] Rha(2S)-1,3-Rha(2Ac)-1,3-Rha(2S)-1,3-Rha(2Ac)-1,3-Rha(2S)-1,3-Rha(2Ac);
[0149] Rha(2S)-1,3-Rha(2Ac)-1,3-Rha(2S)-1,3-Rha(2Ac)-1,3-Rha-1,3-Rha(2Ac,4S);
[0150] Rha(2S)-1,3-Rha(2Ac)-1,3-Rha-1,3-Rha(2Ac)-1,3-Rha(2S)-1,3-Rha(2Ac,4S) ;Rha(2S)-1,3-Rha(2Ac)-1,3-Rha-1,3-Rha-1,3-Rha(2Ac,4S)-1,3-Rha(2Ac,4S).
[0151] It was demonstrated that within the acetylated rhamnosine domain, sulfate groups are bound to the C2 position of rhamnosine, and acetyl groups are bound to the C2 position of rhamnosine, with both substituents alternating on the rhamnosine sugar chain. A small amount of rhamnosine on the sugar chain exhibits both C2 acetylation and C4 sulfation simultaneously.
[0152] 5.4 HILIC-HCD MS / MS Analysis of Acetylated Hexose Sulfate-Rhamnose Oligosaccharides
[0153] (1) Structural analysis of the trisaccharide Hex1Rha2S2:
[0154] The HCD MS / MS spectrum of hexose-rhamnosyltrisaccharide Hex1Rha2S2 (m / z = 315.0396, z = 2) is shown below. Figure 19 As shown, the molecular structure diagram is as follows: Figure 20 As shown, the trisaccharide structures were determined to be Rha(2S)-Hex-Rha(4S) and Rha(2S)-Rha-Hex(4S).
[0155] (2) Structural analysis of Hex2Rha2S2:
[0156] The HCD MS / MS spectrum of hexose sulfate-rhamnite tetrasaccharide Hex2Rha2S2 (m / z = 396.0655, z = 2) is as follows: Figure 21 As shown, the molecular structure diagram is as follows: Figure 22 As shown, the tetrasaccharide structure has two isomers: Rha(2S)-Hex-Rha(4S)-Hex and Rha(2S)-Hex-Rha-Hex(4S). This demonstrates that the hexose sulfate-rhamnose domain is mainly composed of alternating hexose and rhamnose groups, with sulfate ions primarily located at C2 and C4 of the rhamnose group, and a small amount of sulfate ions attached to the C4 position of the hexose group.
[0157] (3) The structure of Hex3Rha3S3+Ac2
[0158] The HILIC-ESI-MS / MS spectrum of the parent ion (m / z=421.0766, z=3) of acetylated hexose sulfate-rhamnohexose Hex3Rha3S3+Ac2 is shown below. Figure 23 As shown, the molecular structure diagram is as follows: Figure 24As shown, the structure that determines the existence of three isomers of this hexasaccharide is:
[0159] Rha(2S)-1,3-Hex(2Ac)-1,3-Rha(2S)-1,3-Hex(2Ac)-1,3-Rha-1,3-Hex(4S);
[0160] Rha(2S)-1,3-Hex(2Ac)-1,3-Rha(2S)-1,3-Hex(2Ac)-1,3-Rha(2S)-1,3-Hex;
[0161] Rha(2S)-1,3-Hex(2S)-1,3-Rha(2Ac)-1,3-Hex(2Ac)-1,3-Rha-1,3-Hex(4S);
[0162] Rha(2S)-1,3-Hex(2Ac)-1,3-Hex(2S)-1,3-Rha(2Ac)-1,3-Rha-1,3-Hex(4S)
[0163] In the acetylated hexose-rhamnose domain, acetyl and sulfate groups are alternately linked on the sugar chain. The acetyl group is primarily bonded to the C2 position of the hexose, with a small number of acetyl groups bonded to the C2 position of the rhamnose. The sulfate group is primarily bonded to the C2 position of the rhamnose, with a small number of sulfate groups bonded to the C2 or C4 positions of the hexose.
[0164] (4) Structural analysis of Hex3Rha3S3+Me2:
[0165] The HILIC-ESI-MS / MS spectrum of methylated hexose sulfate-rhamnosaccharide Hex3Rha3S3+Me2 (m / z = 564.1360, z = 2) is shown below. Figure 25 As shown, the molecular structure diagram is as follows: Figure 26 As shown, the structures of the three isomers of the hexasaccharide are:
[0166] Rha(4S)-1,3-Hex-1,3-Rha(4S)-1,3-Hex-1,3-Rha(2,4Me)-1,3-Hex;
[0167] Rha(4S)-1,3-Hex-1,3-Rha(2Me,4Me)-1,3-Rha-1,3-Hex-1,3-Hex(4S);
[0168] Rha(4S)-1,3-Hex-1,3-Rha-1,3-Hex(2Me,4Me)-1,3-Rha-1,3-Hex(4S).
[0169] The structure of the hexasaccharide indicates that the sulfate group is mainly bound to the C4 position of rhamnose, with the methyl group primarily located at the C4 position of both rhamnose and hexose. Some rhamnose and hexose have dimethyl substitutions at the C2 and C4 positions.
[0170] Verification Example 6: Detection of the antiplatelet aggregation activity of acetylated galactopyranoside-rhamnose
[0171] 1. Test Methods
[0172] 1.1 Preparation of platelet-rich and washed platelets:
[0173] Rats were anesthetized with 15% urethane, and blood was collected from the abdominal aorta. Anticoagulation was performed using 3.8% sodium citrate (v / v 1:9), and the blood was immediately centrifuged at 800 r / min for 10 min. The supernatant was collected as platelet-rich plasma. The remaining blood was further centrifuged at 3000 r / min for 10 min, and the supernatant was collected as platelet-anemic plasma. The platelet count in platelet-rich plasma adjusted from anemic to platelet-rich plasma was approximately 4 × 10⁻⁶. 8 / mL. Platelet-rich plasma was centrifuged at 3000 rpm for 2 min, the supernatant was discarded, and platelet precipitate was obtained. The precipitate was slowly washed twice with Wash Buffer, resuspended in Suspension Buffer, and platelet activity was assessed using the trypan blue rejection test. To ensure a viable cell rate >90%, the platelet concentration was adjusted to 4 × 10⁹ / mL. 8 / mL.
[0174] 1.2 Detection of thrombin-induced platelet aggregation rate and platelet aggregation factor in rats:
[0175] Platelet aggregation capacity was determined using a turbidimetric method. The experiment included a platelet blank group, a thrombin-induced group, a heparin sodium group, and a rhamnose group (30 μg / mL and 70 μg / mL). Physiological saline was used as a blank control, and heparin sodium as a positive control. 300 μL of platelet-rich plasma was added to a sample cup, followed by 25 μL of low molecular weight heparin or rhamnose sulfate solution, and incubated at 37℃ for 5 min. Except for the blank group, 25 μL of bovine thrombin was added to each group to a final concentration of 1.0 U / mL. The absorbance at 660 nm was measured using a turbidimetric method in a platelet aggregator, and the maximum platelet aggregation rate within 5 min was calculated. Aggregation rate (A) = (Tt-T0) / (Tmax-T0)×100%, where: T0 = initial transmittance of platelet-rich plasma (set to 0%), Tt = transmittance at time t, and Tmax = transmittance of platelet-poor plasma (set to 100%). Platelet aggregation inhibition rate % = (maximum aggregation rate of thrombin-induced group - maximum aggregation rate of sample group) / maximum aggregation rate of thrombin-induced group × 100.
[0176] After 5 min of reaction, 10 μmol / L indomethacin was quickly added to terminate the reaction. The samples were centrifuged at 3000 r / min for 10 min, and the supernatant serum was collected and stored at -80℃. The release levels of ADP, 5-HT, TXB2, 6-keto-PGF1α, β-TG, P-selectin, PF4, and vWF in each sample were analyzed and compared using an enzyme-linked immunosorbent assay (ELISA) kit.
[0177] 1.3 Detection of platelet deformity:
[0178] 300 μL of platelet-rich plasma was added to a sample cup. The blank control group received physiological saline, the positive control group received 10 μM PGE1, and the rhamnose groups received 35 μg / mL and 70 μg / mL rhamnose, respectively. After incubation at 37℃ for 5 min, 25 μL of 0.1 U / mL bovine thrombin was added. The absorbance at 660 nm was measured using a turbidimetric method in a platelet aggregator, and the waveform of the absorbance curve during platelet aggregation was observed.
[0179] 1.4 Statistical Analysis:
[0180] All test results are expressed as mean ± standard deviation (%) The mean ± standard deviation (s) is used to represent the statistical significance of differences between groups. The t-test and ANOVA were used for statistical analysis. A p-value < 0.05 was considered statistically significant.
[0181] 2. Experimental Results:
[0182] 2.1 Inhibitory effect of acetylated galactosulfate-rhamnose on thrombin-induced platelet aggregation
[0183] This experiment used an in vitro thrombin-induced platelet aggregation model to study the anti-platelet aggregation activity of acetylated galactosulfate-rhamnose. Thrombin addition induced platelet aggregation. The results are shown in Table 5. In the positive control group, the addition of 7.15 μg / mL and 17.85 μg / mL heparin sodium reduced the platelet aggregation rate to 56.71% and 12.89%, respectively. However, the addition of 35–70 μg / mL acetylated galactosulfate-rhamnose significantly reduced the thrombin-induced platelet aggregation rate. Furthermore, higher concentrations resulted in higher anti-aggregation activity. This indicates that acetylated galactosulfate has excellent inhibitory activity against thrombin-induced platelet aggregation and has the potential to inhibit platelet-related thrombosis and cardiovascular diseases.
[0184] Table 5. Effects of rhamnose sulfate on thrombin-induced platelet aggregation ( ±s)
[0185] 7.15 μg / mL 15 μg / mL 35 μg / mL 50 μg / mL 70 μg / mL Thrombin induction group 85.31±4.15 85.31±4.15 85.31±4.15 85.31±4.15 85.31±4.15 Heparin sodium 56.71±4.32 12.89±3.54 - - - Rhamnose group 83.91±7.73 74.54±7.01 57.77±3.19 42.59±8.16 36.15±4.62
[0186] 2.2 Effects of acetylated galactosulfate-rhamnose on platelet aggregation factor release:
[0187] When thrombin activates platelets, the dense granules of platelets release large amounts of ADP and 5-HT, which is one of the important inducing factors for platelet aggregation. The effect of acetylated galactosulfate-rhamnian polysaccharide on the ability of thrombin to induce the release of ADP and 5-HT from dense platelet granules in mice is as follows: Figure 27 As shown, compared with the control group, platelets in the thrombin-induced group released a large amount of ADP and 5-HT after thrombin induction. However, the addition of 35 and 70 μg / mL acetylated galacto-rhamnose sulfate significantly reduced the release of ADP and 5-HT from platelets, similar to the effect of the positive control of 17.85 μg / mL heparin sodium. This indicates that rhamnose sulfate can effectively inhibit the release of aggregation-promoting factors ADP and 5-HT from platelet dense granules, thereby inhibiting platelet aggregation.
[0188] Platelet factor 4 (PF4) is one of the specific proteins synthesized and secreted by platelet α-granules. It readily binds to and neutralizes heparin, thus slowing down the thrombin inactivation process and promoting platelet aggregation. β-thromboglobulin (β-TG) is a platelet-specific globulin, a homotetramer derived from PF4. Under the stimulation of an inducer, it is released from platelet α-granules into the plasma. Measuring the plasma β-TG content reflects the platelet-specific release response. The effects of acetylated galactosulfate-rhamnose on the ability of thrombin-induced release of PF4 and β-TG from mouse platelet α-granules are as follows: Figure 28 As shown, in the model group, the addition of thrombin induced the release of large amounts of PF4 and β-TG from platelets, thereby promoting platelet aggregation. However, the release of PF4 and β-TG from platelets in the groups with added 35 and 70 μg / mL rhamnose was significantly reduced, indicating that rhamnose sulfate can inhibit thrombin-induced platelet α-granule secretion and inhibit the release of aggregation-promoting factors PF4 and β-TG from platelet α-granules, thus inhibiting platelet aggregation.
[0189] Thromboxane A2 (TXA2) is produced via the arachidonic acid metabolic pathway, metabolized by cyclooxygenase (COX). Due to its short half-life, TXA2 is usually indirectly reflected by the content of thromboxane B2 (TXB2). Prostacyclin (PGI2) is an antagonist of thromboxane; its synthesis prevents the formation of platelet aggregates. The content of 6-keto-prostacyclin 1α (6-keto-PGF1α) is usually measured to reflect the PGI2 content in platelets. The effect of acetylated galactosulfate-rhamnose on the ability of thrombin-induced release of TXB2 and PGF1α from mouse platelets is as follows... Figure 29As shown, in the model group, platelets released a large amount of TXB2 after thrombin induction, while the level of 6-keto-PGF1α decreased significantly, reaching only half that of resting platelets. Compared with the model group, the TXB2 release from platelets in the groups supplemented with 35 and 70 μg / mL rhamnose was significantly reduced, but the 6-keto-PGF1α content did not change significantly. This indicates that rhamnose significantly inhibits thrombin-induced platelet release of TXB2, but has no effect on PGI2 release.
[0190] 2.3 Effects of rhamnose sulfate on thrombin-induced platelet deformability
[0191] The effect of acetylated galactosulfate-rhamnian on thrombin-induced platelet deformability in mice, as follows: Figure 30 As shown, in the resting state, platelets are biconcave discs. When activated by thrombin, the platelet morphology changes, becoming ellipsoidal, with pseudopodia forming and protruding, resulting in a slight decrease in light transmittance in the sample cell. This is displayed as a downward-sloping waveform on the platelet aggregator, indicating that thrombin activation causes platelet deformation. Figure 30 (B) For example Figure 30 C and Figure 30 Medium-dose PGE1 (10 μmol / L) and high-dose rhamnosine sulfate (70 μg / mL) had no stimulating effect on platelets. Figure 30 China D and Figure 30 Platelets treated with 10 μmol / L PGE1 and 70 μg / mL rhamnosine sulfate simultaneously did not show thrombin-induced platelet deformability, indicating that PGE1 and rhamnosine sulfate have a good inhibitory effect on thrombin-induced platelet deformability.
[0192] The above examples are merely illustrative of the technical concept and features of the present invention and should not be construed as limiting the scope of protection of the present invention. All equivalent transformations or modifications made in accordance with the essence of the present invention should be included within the scope of protection of the present invention.
Claims
1. A method for preparing acetylated galactopyranosulfate-rhamnose, characterized in that, Includes the following steps: (1) Prepare a suspension of Chlorella powder with distilled water and break the cell wall in a microfluidic homogenizer to obtain a cell wall broken algae solution; (2) Add a mixture of alkaline protease and neutral protease to the broken algae solution and enzymatically hydrolyze for 24 h. Then, inactivate the enzyme by boiling water bath, cool and centrifuge, collect the supernatant, and concentrate under vacuum to obtain the enzymatic hydrolysate. (3) Add ethanol to the enzymatic hydrolysate for precipitation, then centrifuge and discard the supernatant. Collect the solid as Chlorella crude polysaccharide. (4) The crude polysaccharide was dissolved in distilled water and separated and purified using a DEAE-Sepharose Fast Flow column. It was eluted with distilled water, 0.2 mol / L sodium chloride solution and 0.4 mol / L sodium chloride solution, respectively. The 0.4 mol / L sodium chloride solution eluent was collected and subjected to ultrafiltration membrane desalting, vacuum concentration and freeze drying to obtain the acetylated galactopyranoside sulfate.
2. The preparation method according to claim 1, characterized in that, In step (1), the solid-liquid ratio of the dried Chlorella powder and distilled water is 0.5-1.5:2-4 g:mL; in step (2), the alkaline protease is a serine protease; the neutral protease is trypsin, and the mass ratio of alkaline protease to neutral protease is 2-3:1-2; in step (3), 90% ethanol is added to the enzymatic hydrolysate, and the volume ratio of the enzymatic hydrolysate to ethanol is 0.5-1.5:7-9.
3. An acetylated galactopyrostan obtained by the preparation method according to any one of claims 1-2, characterized in that, The acetylated galactosulfate-rhamnosaccharide has a weight-average molecular weight of 20.42 kDa, a dispersion index of 2.43, a sulfate molar content of 12.75%, and a protein content of 2.45%.
4. The acetylated galactopyranoside according to claim 1, characterized in that, The acetylated galactosulfate-rhamnose polysaccharide has the following monosaccharide molar composition: rhamnose 36.6%, galactose 30.4%, glucose 9.4%, mannose 5.4%, glucosamine 5.6%, arabinose 5.0%, xylose 3.7%, glucosamine 1.5%, and glucuronic acid 2.4%.
5. The acetylated galactopyranosan according to claim 1, characterized in that, The acetylated galactosulfate-rhamnose contains four domains and one branch: an acetylated hexose sulfate domain, a rhamnose sulfate domain, an acetylated rhamnose sulfate domain, an acetylated and methylated hexose-rhamnose sulfate domain, and a hexose disaccharide branch.
6. The acetylated galactopyranosan according to claim 5, characterized in that: The acetylated hexose sulfate domain has a main chain composed of 2-4 →3-α-D-hexose residues, modified with 1-2 sulfate groups and 1-3 acetyl groups; the hexose residues are selected from galactose, glucose or mannose; The rhamnose sulfate domain has a main chain composed of 2-4 oligosaccharides consisting of 3-α-D-rhamnose-1 repeating units, each oligosaccharide being modified by 1-2 sulfate groups. The acetylated rhamnose sulfate domain has a main chain composed of 3-8 oligosaccharides consisting of 3-8 →3-α-D-rhamnose-1→ repeating units, each oligosaccharide having 2-3 sulfate groups and 1-5 acetyl groups modified on it. The acetylated and methylated hexose sulfate-rhamnose domains are mainly composed of repeating disaccharide units Hex1→3Rha linked alternately with galactose, mannose, glucose, and rhamnose in 1→3 bonds, and the oligosaccharides have sulfate, acetyl, and methyl substitutions. The hexose sulfate disaccharide branched chain is a disaccharide composed of glucose, galactose, glucose or mannose with 1,3 glycosidic bonds, and the hexose has sulfate modification at the C2 and C4 positions.
7. The use of the acetylated galactosulfate-rhamnose of claim 3 in the preparation of a drug for inhibiting platelet aggregation and deformability.
8. The use of the acetylated galactosulfate-rhamnose according to claim 3 in the preparation of a drug for inhibiting platelet aggregation factors.
9. The use of the acetylated galactosulfate-rhamnose according to claim 3 in the preparation of drugs for the prevention and treatment of platelet-related diseases, characterized in that, The platelet-related diseases mentioned refer to any one or more of the following: thrombosis, coronary heart disease, angina pectoris, and acute myocardial infarction.
